Clinical Trials Logo

Clinical Trial Summary

Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide. The cause of developing BC is currently unknown. However, there are several risk factors, such as volumetric breast density (VBD), which have been proved to have a relationship with BC. The assessment of breast density is typically performed subjectively using the 4-classes density classification described by American College of Radiology. However, in the last years, automated breast density software tools have been developed (e.g. Volpara, Quantra). In this work, VBD measurements from VolparaTM (v. 1.5.4.0) will be compared between Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) of the same pacient ('combo mode'). Images will be acquired in a Hologic Selenia Dimensions, the most common FFDM/DTB system, where image resolution is different for FFDM (70 um) and DBT (140 um).

This study (1) evaluates the consistency between Volpara's breast density measurements and spatial distribution for the two imaging techniques (FFDM and DBT) in a Hologic Selenia Dimensions, and (2) compares VDB measurements with other similar tool (Quantra) and radiologists breast density manual classification.


Clinical Trial Description

Monocentric, prospective and observational study which will analyse a series of 300 cases (FFDM + DBT) from consecutive women. Image acquisitions will take place within the Área de radiología Mamaria y Ginecológica located at Parc Taulí Hospital Universitari, Sabadell. The purposes of this study will be explained to each potential candidate and if agreed to participate, a consent form will be signed.

Inclusion criteria:

- Subjects over 18 years old.

- Acceptance of participation through a signed consent form.

- Asymptomatic subjects

Exclusion criteria:

- Subjects refusing to participate or sign the consent form.

- Subjects with prior history of breast surgery or biopsy with markers.

- Subjects with breast prostheses. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04127175
Study type Observational
Source Corporacion Parc Tauli
Contact Oliver Diaz, PhD
Phone +34 93 402 08 55
Email oliver.diaz@ub.edu
Status Recruiting
Phase
Start date October 1, 2019
Completion date August 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04904757 - Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening N/A
Completed NCT00470561 - Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density N/A
Recruiting NCT04498013 - Study of the Effects of Cyclodynon on Reducing the Cumulative Risk of Breast Cancer Development in a Female Aged 40-52 Phase 4
Terminated NCT03199963 - Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue Phase 3
Completed NCT04616430 - Topical Endoxifen in Women Phase 2